Intranasal Esketamine Versus Other Pharmacological Strategies in Treatment-Resistant Depression with High Suicide Risk: A Six-Month Naturalistic Study.
Clinics and practice June 12, 2026 Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.
In a six-month naturalistic study of 62 patients with treatment-resistant depression and high suicide risk, those receiving intranasal esketamine showed faster and greater reductions in suicidal thoughts and depressive symptoms compared to those receiving alternative pharmacological treatments. The number needed to treat to prevent one case of high suicide risk was 1.35. Functional improvement was similar between groups. The findings support esketamine as a rapid-acting option in real-world, closely monitored care.